2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2410

Report from the International Consortium of Health Outcome Measurement Hip and Knee Osteoarthritis Working Group: Consensus on an International Standard Set of Outcomes Measures for Patients with Hip or Knee Osteoarthritis.
Abstract Number: 727

Repository Corticotropin Injection (H.P. Acthar® Gel) Attenuates Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus (SLE) Requiring Corticosteroids
Abstract Number: 2544

Representing the Variability in Patients’ Preferences
Abstract Number: 203

Rescue of Copa Syndrome Cellular Phenotype By Autophagy Modifying Drugs
Abstract Number: 2078

Reserve Capacity: Explaining the Link Between Socioeconomic Status and Depression/Anxiety Among Patients with Systemic Lupus Erythematosus
Abstract Number: 1140

Resident Non-Classical Monocytes Are Critically Important for Tissue Destruction in Arthritis
Abstract Number: 2227

Resident’s Guide to Pediatric Rheumatology Mobile App: Assessing Enablers and Barriers of Use through Qualitative Focus Groups
Abstract Number: 1264

Residential Proximity to Highways, DNA Methylation and Systemic Lupus Erythematosus
Abstract Number: 151

Residual Synovitis in Ultrasound (US) Is Associated with an Evolution Towards Rheumatoid Arthritis (RA) in Patients with Inflammatory Polyarthralgia without ANTI-Citrulinated Antibodies (ACPA)
Abstract Number: 1544

Resiliency As a Predictor of Depressive Symptoms in Patients with Rheumatoid Arthritis
Abstract Number: 302

Resource Utilization in a US Sample of Patients with Sporadic Inclusion Body Myositis
Abstract Number: 2308

Responder Compared to Mean Change Analyses in a Fibromyalgia Phase 2b Clinical Study of Bedtime Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL)
Abstract Number: 2313

Responder Rates and Numbers Needed to Treat Based on Clinically Meaningful Improvements in Patient Reported Outcomes (PROs) Including Health-Related Quality of Life (HRQoL) after Sarilumab Treatment during a Phase III Randomized Controlled Trial (RCT)
Abstract Number: 1753

Response Gene to Complement-32 Promotes Plasma Cell Differentiation and Enhances Lupus-like Chronic Graft Versus Host Disease
Abstract Number: 1050

Response to Baricitinib at 4 Weeks Predicts Response at 12 and 24 Weeks in Patients with Rheumatoid Arthritis: Results from Two Phase 3 Studies

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].